It is made available under a CC-BY-NC-ND 4.0 International license .

1 Digital PCR discriminates between SARS-CoV-2 Omicron variants and immune escape

2 mutations

- 3 Steven C. Holland¹, LaRinda A. Holland¹, Matthew F. Smith¹, Mihyun B. Lee¹, James C. Hu¹,
- 4 Efrem S. Lim
- ⁵ ¹Center for Fundamental and Applied Microbiomics, Biodesign Institute, Arizona State
- 6 University
- 7 ²School of Life Sciences, Arizona State University
- 8
- 9 Running title: SARS-CoV-2 variant and immune escape dPCR assays

10

11 #Address correspondence to Efrem S. Lim, <u>Efrem.Lim@asu.edu</u>

It is made available under a CC-BY-NC-ND 4.0 International license .

12 ABSTRACT

13	As SARS-CoV-2 continues to evolve, mutations arise that will allow the virus to evade immune
14	defenses and therapeutics. Assays that can identify these mutations can be used to guide
15	personalized patient treatment plans. Digital PCR (dPCR) is a fast and reliable complement to
16	whole genome sequencing that can be used to discriminate single nucleotide polymorphisms
17	(SNPs) in template molecules. Here, we developed a panel of SARS-CoV-2 dPCR assays and
18	demonstrate its applications for typing variant lineages and therapeutic monoclonal antibody
19	resistance. We designed multiplexed dPCR assays for SNPs located at residue 3395 in the orf1ab
20	gene and residue 143 of the <i>spike</i> gene that differentiate the Delta, Omicron BA.1, and Omicron
21	BA.2 lineages. We demonstrate their validity on 596 clinical saliva specimens that were
22	sequence-verified using Illumina whole genome sequencing. Next, we developed dPCR assays
23	for spike mutations R346T, K444T, N460K, F486V, and F486S mutations that are associated with
24	host immune evasion and reduced therapeutic monoclonal antibody efficacy. We demonstrate
25	that these assays can be run individually or multiplexed to detect the presence of up to 4 SNPs
26	in a single assay. We validate these dPCR assays on 81 clinical saliva SARS-CoV-2 positive
27	specimens from Omicron subvariants BA.2.75.2, BM.1.1, BN.1, BF.7, BQ.1, BQ.1.1, and XBB.
28	Thus, dPCR could serve as a useful tool to determine if clinical specimens contain
29	therapeutically relevant mutations and inform patient treatment.

30

31 Keywords

32 SARS-CoV-2, Digital PCR, monoclonal antibody, immune escape mutations, clinical diagnostics

It is made available under a CC-BY-NC-ND 4.0 International license .

33 INTRODUCTION

The evolution of SARS-CoV-2 brings challenges to disease epidemiology and patient treatment. 34 35 Genomic mutations arise that define phylogenetic lineages, alter virus properties, and have functional consequences of clinical significance (1). In early November, 2021, the SARS-CoV-2 36 37 Delta variant and its sublineages were the predominantly circulating lineages in the United States (2). On November 26, 2021 the World Health Organization designated the SARS-CoV-2 38 Omicron variant as a "variant of concern" (3). Genome sequencing showed that the Omicron 39 40 lineages contained approximately 50 unique mutations compared to previous variants of 41 concern (4). Phylogenetic analysis indicated that the Omicron lineages arose independent of 42 the Delta lineage, likely from a prolonged infection in an immunocompromised patient, or an 43 animal host (5). The Omicron BA.1 lineage eventually rose to be the dominant circulating lineage, displacing Delta lineages at a rate faster than previous variants (6). This increased rate 44 45 of displacement is likely due to increased immune evasion and infectivity of the early Omicron BA.1 and BA.2 variants (7-9). 46

Since their initial emergence, Omicron lineages have diversified, with multiple sublineages 47 branching from the ancestral BA.1 and BA.2 lineages. Studies show that currently circulating 48 strains (e.g. BA.2.75.2 and BQ.1.1) are increasingly able to escape neutralization by sera 49 50 obtained from vaccinated individuals, compared to the original BA.2 strain (10). Neutralization 51 by sera from vaccinated individuals that also recovered from an Omicron breakthrough 52 infection (BA.1, BA.2, or BA.5) was also reduced in more recent variants. Worryingly, circulating 53 sublineages have also independently evolved mutations within the receptor binding domain (RBD) of the Spike protein that escape neutralization by the therapeutic monoclonal antibodies 54

It is made available under a CC-BY-NC-ND 4.0 International license .

55	(mAbs) bebtelovimab, bamlanivimab, etesevimab, casirivimab, tixagevimab, and others (11).
56	The R346, K444, L452, N460, E484, and F486 residues may be particularly important in mAb
57	resistance and SARS-CoV-2 pathology (12). Due to the limited methods to determine if a patient
58	is infected with a resistant variant, the FDA issues blanket guidance to withdraw emergency use
59	authorization (EUA) for mAbs based on general variant presence (13). This significantly limits
60	patient access to life-saving treatment options regardless of what variant they are infected with
61	(e.g., co-circulating variants that are susceptible to mAbs). Hence, methods to rapidly
62	determine if SARS-CoV-2 positive patient specimens harbor resistance mutations are of critical
63	importance in guiding therapeutic treatment.
64	Whole genome sequencing is the most comprehensive method for genotyping SARS-CoV-2.
65	However, the cost, time requirements, and required technical expertise leaves a need for
66	complementary methods to identify variants of concern and mutations of interest in clinical
67	specimens. Digital PCR (dPCR) has emerged as a technology that can be used to detect and
68	differentiate single nucleotide polymorphisms (SNPs) in template DNA (14). In the QuantStudio
69	Absolute Q Digital PCR system (ThermoFisher, Massachusetts, USA), template DNA is
70	partitioned into over 20,480 microchambers. Within each microchamber, an end-point PCR
71	reaction is performed which contains primers and probes specific to template DNA. TaqMan
72	(ThermoFisher, Massachusetts, USA) probes contain a fluorescent dye and fluorescent
73	quencher molecule affixed to opposing ends of the probe oligomers. During the PCR elongation
74	phase, polymerase activity degrades annealed probes, liberating the fluorescent dye from the
75	quencher molecule and allowing fluorescence emission (15). Probe length is an important
76	factor in facilitating fluorescence quenching, so minor groove binder (MGB) moieties can also

It is made available under a CC-BY-NC-ND 4.0 International license .

77	be attached to probes to reduce probe length and improve quencher efficiency (16). After the
78	PCR assay has completed, end-point fluorescence intensity is then used to determine whether a
79	microchamber is 'positive' or 'negative' for each probe target and the number of positive
80	microchambers can be used to calculate template presence (17). The robustness and sensitivity
81	of dPCR to detect template differences of only a single nucleotide have made it useful in
82	practical applications of viral identification and quantitation, determination of allelic imbalance,
83	and wastewater viral variant surveillance (18-20).
84	In this study, we demonstrate the usefulness of dPCR in detecting polymorphisms in SARS-CoV-
85	2 genomes obtained from clinical saliva specimens. We show that dPCR can detect the
86	presence of one or two SNPs to distinguish between the Delta, Omicron BA.1, and Omicron
87	BA.2 lineages. We also show that a nine-nucleotide deletion can be used to identify the
88	Omicron BA.1 lineage. We verify the clinical validity of these assays by determining lineage
89	designations for 596 SARS-CoV-2 positive clinical saliva samples and verify those determinations
90	by Illumina next generation sequencing. We finally demonstrate the ability of dPCR to identify
91	mutations at up to 4 genomic loci in a single reaction vessel and use this ability to detect SNPs
92	associated with immune escape in 81 clinical saliva samples.

93 MATERIALS AND METHODS

94 Saliva specimens and diagnostic testing

95 This study was approved by Arizona State University Institutional Review Board. This study

96 involved analyses of 677 saliva specimens submitted for SARS-CoV-2 testing at ASU Biodesign

97 Clinical Testing Laboratory (ABCTL) from November 16, 2021 to December 10, 2022. Saliva

It is made available under a CC-BY-NC-ND 4.0 International license .

samples were independently collected by participants in 2 mL collection vials, registered, and

98

99 deposited at drop-off locations. RNA was extracted from 250µl of saliva specimen within 33 hours of sample receipt using the KingFisher Flex (Thermo Scientific), following the 100 manufacturer's guidelines. Diagnostic testing was performed using TaqPath COVID-19 Combo 101 102 Kit assay (Applied Bio-systems, USA) following manufacturer's guidelines. **Digital PCR** 103 DNA constructs (primers, probes, template constructs) were ordered from either Integrated 104 DNA technologies (Coralville, IA, USA) or Applied Biosystems (Waltham, MA, USA; nucleotide 105 106 sequences can be found in Tables S1, S2, and S3 in the supplemental material). 107 The reaction mixtures for the *orf1ab* and *spike* lineage discriminating assays were comprised of 108 1X Absolute Q 1-step RT-dPCR Master Mix (Applied Biosystems, Waltham, MA), 400 nM of each primer, 200 nM of each fluorescent probe, 4 µL template, water was used to bring the final 109 volume to 9µL. Synthetic DNAs were assayed at a concentration of 10^3 copies/µL. Saliva 110 specimens with threshold cycle (C_t) values less than 19 when assayed using TaqPath COVID-19 111 112 Combo Kit assay (Applied Bio-systems, USA) were diluted 1:2 before loading. 113 The reaction mixtures for the *spike* RBD mutation assays were comprised of 1X Absolute Q 1-114 step RT-dPCR Master Mix (Applied Biosystems, Waltham, MA), 450 nM of each primer, 280 nM of each fluorescent probe, 5.5 µL template, water was used to bring the final volume to 9µL. 115 Synthetic DNAs were assayed at a concentration of 10^3 copies/ μ L. 116 Samples were loaded in QuantStudio Absolute Q MAP16 (Applied Biosystems, Waltham, MA), 117 overlaid with 15 µL Absolute Q Isolation Buffer (Applied Biosystems, Waltham, MA), and the 118

It is made available under a CC-BY-NC-ND 4.0 International license .

119	digital PCR reactions were performed on the Absolute Q dPCR system (Applied Biosystems,
120	Waltham, MA). For the <i>orf1ab</i> and <i>spike</i> lineage determination assays, cycling conditions were:
121	10 min at 50°C, 5 min activation at 95°C, 40 cycles of 2s at 95°C and 15s at 54°C. For the <i>spike</i>
122	RBD assay determination assays, cycling conditions were: 10 min at 50°C, 5 min activation at
123	95°C, 40 cycles of 2s at 95°C and 25s at 58°C. Fluorescence intensities and positive chamber
124	counts were analyzed using QuantStudio Absolute Q Digital PCR Software version 6.2.0 (Applied
125	Biosystems, Waltham, MA). Results for clinical specimens can be found in the supplemental
126	material datasets 1 - 5.
127	SARS-CoV-2 genome sequencing
128	NGS library preparation for saliva samples was performed using the COVIDSeq Test
129	(Illumina, San Diego, CA, USA) with ARTICv4 and ARTICv4.1 primer sets (21). Libraries were
130	sequenced on the Illumina NextSeq2000 instrument using 2×109 paired end reads. Sequencing
131	reads adapter sequences were trimmed using trim-galore, aligned to the Wuhan1 reference
132	genome (MN908947.3) using the Burrows–Wheeler aligner, BWA-MEM version 0.7.17-r1188
133	(22), and had their primer sequences trimmed using iVAR version 1.3.1 (23). Lineage calling for
134	community and hospital-derived sequencing data was performed with pangolin software (24),
135	with its assignment and designation libraries up to date at the time of analysis. Sequence
136	quality was validated and annotated using VADR version 1.4 (25).
137	Phylogenetic analysis

Phylogenies were generated using Nextstrain.cli version 5.0.1 (26) and associated Augur
Auspice pipeline with an input dataset based on the Nextstrain ncov GISAID Reference dataset

It is made available under a CC-BY-NC-ND 4.0 International license .

140	accessed on November 16 th , 2022. Duplicate lineages were removed, and the set was
141	supplemented with lineages of interest in which assay-targeted mutations were found to be
142	present in at least 75% of sequences. The Nextstrain ncov default build was utilized, with a
143	minimal config file specifying the input dataset and Wuhan/Hu-1/2019 as the root. The filter
144	settings in the default parameters file were modified by setting the skip_diagnostics flag to
145	true.
146	Global mutation proportion analysis
147	Global mutation proportion data were downloaded from cov-spectrum (27) with simple queries
148	for S:R346T, S:K444T, S:N460K, S:F486S, and S:F486V. Absolute counts were downloaded in
149	addition to proportion data for S:N460K. An advanced query was performed to obtain absolute
150	counts for each codon (AAA, AAG) present in S:N460K sequences. Data were plotted from
151	March 3 rd , 2022 until November 6 th , 2022. For plotted data range, the difference in 95% CI top
152	and 95% CI bottom never reaches greater than 5%)
153	
154	RESULTS
155	Digital PCR assay to distinguish Delta, Omicron BA.1, and Omicron BA.2 utilizing two SNPs in
156	the <i>orf1ab</i> gene.
157	Since the effectiveness of therapeutic treatments can differ between SARS-CoV-2 lineages, a set
158	of dPCR probes was designed to discriminate between the Delta, Omicron BA.1, and BA.2
159	lineages using SNPs found in the <i>orf1ab</i> gene (Fig 1A). The probes hybridize at nucleotides

It is made available under a CC-BY-NC-ND 4.0 International license .

160	10440-10454, located in the <i>orf1ab</i> gene, and are used to detect substitutions found in the
161	Delta and Omicron lineages located at amino acids R3394 and P3395. The probe homologous to
162	the Delta lineage sequence uses VIC as its fluorescent dye and shares the same nucleotide
163	sequence as the Wuhan1 reference sequence over the probe region. The Omicron BA.1 probe
164	discriminates between the Delta sequence at the c10449a nucleotide substitution (amino acid
165	P3395H) and uses FAM as its fluorescent dye. The Omicron BA.2 probe discriminates between
166	the Delta sequence at the c10449a (amino acid P3395H) and g10447a (synonymous mutation in
167	R3394) nucleotide substitutions and uses NED as its fluorescent dye. The fluorescent dyes were
168	connected to the 5' end of the oligo and all three probes contain a minor groove binder (MGB)
169	moiety on the 3' end of the oligo to improve binding to template sequence (15).
170	The efficacy and specificity of probes were tested using synthetic DNA constructs (Fig 1B). The
171	Delta (VIC), Omicron BA.1 (FAM), and Omicron BA.2 (NED) probes showed a clear fluorescence
172	response when assayed with their homologous templates. The Omicron BA.1 probe also
173	showed a fluorescence response to the Delta and Omicron BA.2 templates. This signal was
174	lower in fluorescence intensity than observed from Omicron BA.1 templates, but higher than
175	the negative signal observed in reactions containing no template DNA. There was a negligible
176	response of the Delta (VIC) and Omicron BA.2 (NED) probes when used on their mismatching
177	templates. Fluorescence threshold values for each probe were set to exclude the range of
178	negative values found in mismatching templates. The fluorescence threshold for Omicron BA.1
179	(FAM) was set above the non-specific fluorescence values observed in the mismatching
180	template assays.

It is made available under a CC-BY-NC-ND 4.0 International license .

181	In order to determine the validity of the orf1ab dPCR assay on clinical specimens, we performed
182	the 3-probe multiplex dPCR assay and Illumina next-generation sequencing on 596 SARS-CoV-2
183	positive saliva samples. To receive a 'positive' result for a particular probe, the sample required
184	9 or more microchambers to have a fluorescence intensity above the threshold value. During
185	the dPCR assay scoring, Illumina sample lineages were blinded to scorers. Using this criteria,
186	540 samples tested positive for a single lineage using the dPCR assay. All 540 samples had
187	lineage designations by dPCR concordant with Illumina whole genome sequencing designations.
188	No samples displayed a positive response from probes discordant to the genome sequencing
189	designations (Fig 1C; also see Supplementary Dataset
190	1 in the supplemental material). There were 56 samples in which no probe passed the positive
191	chamber count. C _t values of these negative samples were found to be significantly higher than
192	samples with positive outcomes, indicating that viral load contributes to assay efficacy (Positive
193	samples median C _t = 22.05, Negative samples median C _t = 24.34, $p < 0.0001$; Mann-Whitney
194	test). Together, this demonstrates that dPCR can use two nucleotide polymorphisms to
195	discriminate the Delta, Omicron BA.1, and Omicron BA.2 lineages in saliva specimens.

It is made available under a CC-BY-NC-ND 4.0 International license .



196

Fig 1: Digital PCR assay for the determination of the Delta, Omicron BA.1, and Omicron BA.2 197 lineages. (A) Schematic showing annealing locations of primers (black arrows) and probes 198 (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities of dPCR 199 microchambers for synthetic DNA constructs. Positive microchambers are those exceeding 200 201 fluorescence thresholds (shaded regions). (C) Number of positive microchambers (maximum 202 number of chambers is 20480) resulting from each saliva sample. Samples are grouped by Illumina sequencing lineage determination and sorted by positive microchamber count of the 203 respective lineage-specific probe. Dotted line indicates the positive threshold value (9 204 microchambers). 205

It is made available under a CC-BY-NC-ND 4.0 International license .

207 Digital PCR assay to distinguish between Omicron BA.1 and Delta/Omicron BA.2 utilizing a

208 nine-nucleotide deletion in the *spike* gene.

- 209 Some therapeutic antibodies, like sotrovimab, are still partially effective against the Omicron
- BA.1 lineage but less effective against the BA.2 lineage (11), we sought to design an assay to
- discriminate the Omicron BA.1 lineage from Delta and BA.2. We found a nine-nucleotide
- deletion within the Spike protein coding region (G21987-T21995, amino acids G142-Y145)
- 213 specific to the BA.1 lineage. We designed dPCR probes to either contain only the nucleotides
- flanking the deleted region or to contain the nucleotides found in the deletion (Fig 2A). These
- sequences would provide identity to the Omicron BA.1 lineage, or to the Delta and Omicron
- BA.2 lineages, respectively. Probes contained either the VIC (BA.1) or FAM (Delta/BA.2)

fluorescent dye on the 5' end and both probes contained a 3' MGB moiety.

- 218 The dPCR probes were validated on synthetically produced DNA templates. Each probe
- displayed a high fluorescence signal when assayed with its matching template (Fig 2B). No

evidence of a secondary fluorescence signal band, as seen in the *orf1ab* Omicron BA.1 probe

- (Fig 1B), was observed in either probe (Fig 2B). Fluorescence thresholds were set by excluding
- 222 fluorescence intensity values from mismatching control templates.
- The S gene dPCR assay was performed on the same 596 SARS-CoV-2 positive clinical saliva samples assayed on the *orf1ab* assay. Sample positivity was scored as above, blinded and using the 9 microchambers as the positive threshold criterion. Using this method, 512 samples tested positive from a single probe. All 512 lineage designations from Illumina whole genome sequencing were in concordance with the digital PCR assay. No sample tested positive to a

It is made available under a CC-BY-NC-ND 4.0 International license .

dPCR probe that was discordant to its lineage designation from whole genome sequencing (Fig 228 229 **2C**; also see Supplementary Dataset 2 in the supplemental material). There were 84 samples in which no probe passed the positive threshold value. C_t values of samples with no positive 230 results were found to be significantly higher than positive samples, indicating that viral load 231 232 contributes to assay efficacy (Positive samples median $C_t = 21.88$, Negative samples median $C_t =$ 24.42, *p* < 0.0001; Mann-Whitney test). This demonstrates that the S gene del143-145 deletion 233 can be used to discriminate SARS-CoV-2 Omicron BA.1 lineages from Delta and Omicron BA.2 234 235 lineages in saliva specimens.



Fig 2: Digital PCR assay for the determination of the Omicron BA.1, and Delta or Omicron BA.2
 lineages. (A) Schematic showing annealing locations of primers (black arrows) and probes
 (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities of dPCR
 microchambers for synthetic DNA constructs. Positive microchambers are those exceeding

It is made available under a CC-BY-NC-ND 4.0 International license .

fluorescence thresholds (shaded regions). (C) Number of positive microchambers (maximum
number of chambers is 20480) resulting from each saliva sample. Samples are grouped by
Illumina sequencing lineage determination and sorted by positive microchamber count of the
respective lineage-specific probe. Dotted line indicates the positive threshold value (9
microchambers).

246
247 Digital PCR assays to detect immune evasion-associated SNPs in the Spike protein receptor
248 binding domain.

Another potential diagnostic application is in discerning the presence of amino acid mutations 249 250 that may render therapeutic monoclonal antibodies ineffective. To observe the frequency of Spike RBD mutations that provide immune escape properties, the GISAID database was gueried 251 for SARS-CoV-2 Omicron sequences containing five mutations associated with immune escape: 252 253 R346T, K444T, N460K, F486V, and F486S (10) (Fig 3). The L452R mutation within the Spike RBD 254 region has also been strongly associated with immune escape (10), but has been the subject RT-255 gPCR detection (28), so it was omitted from analysis. We found that many of these mutations 256 are found distributed across multiple sublineages (Fig 3A). We observed that the R346T mutation has been rising in frequency since May 2022 and has arisen in the BA.2, BA.4, and 257 258 BA.5 lineages as well as in the XBB recombinant lineages (Fig 3B). The K444T mutation has been rising in global frequency since September 2022, arising within the BE and BQ sublineages (BE 259 260 and BQ are sublineages of BA.5; Fig 3C). The N460K mutation has arisen within BA.2 and BA.5 261 sublineages and XBB recombinants (Fig 3D). The BA.2 sublineages utilize an AAG codon,

It is made available under a CC-BY-NC-ND 4.0 International license .

whereas the BA.5 lineages utilize an AAA codon. The F486S mutation is slowly becoming more abundant and is seen in BA.2 sublineages and XBB recombinants (**Fig 3E**). The F486V mutation arose earliest and differentiates BA.4 and BA.5 lineages from BA.2 lineages (**Fig 3F**). Taken together, these mutations are becoming more abundant in circulating SARS-CoV-2 lineages and are arising in multiple, independent lineages.

To ensure that dPCR probes were designed with sequences representative of circulating SARS-267 CoV-2 genomes, we queried the GISAID database to determine the codon usage for amino acid 268 269 mutations associated with immune escape. For the R346T, K444T, F486V and F486S mutations, 270 over 99% of genome sequences in the GISAID database utilize a single codon to encode the 271 substituted amino acid (Figs 3A, 3B, 3C, 3E, 3F). However, N460K is encoded by the AAG codon 272 in 54.09% of sequences and by the AAA codon in 45.91% of genomes containing this mutation (Fig 3D). Therefore, two probes were designed to investigate the N460K mutation. Probes 273 274 containing the amino acid found in the Wuhan1 reference sequence at each position were also created at each position. To assess the global applicability of the dPCR assays, we calculated the 275 mismatch frequency at each nucleotide position for all primers and probes against all genome 276 277 sequences in the GISAID database. We found that probes had low mismatch frequency outside of the codon encoding the mutation of interest (see Fig S1 in the supplemental material). 278 Primers also had a low mismatch frequency, however, the F486 assay requires the presence of 279 280 the S477N and T478K mutations for amplicon generation.

It is made available under a CC-BY-NC-ND 4.0 International license .



Fig 3: Phylogenetic distribution of mutations that evade therapeutic monoclonal antibodies. (A)
 Phylogenetic tree of representative circulating sublineages. Colored circles indicate the
 presence of a Spike RBD mutation found in at least 75% of sequences within that lineage.

It is made available under a CC-BY-NC-ND 4.0 International license .

Global frequency, phylogenetic distribution, and codon frequencies for R346T (B), K444T (C),
N460K (D), F486S (E), and F486V (F) mutations.

287

288	Mutation and reference probes were designed to be run independently or multiplexed with
289	other probes. Each mutation/reference pair contained a different fluorescent dye and the
290	mutation probes used a different fluorescent dye between residue locations (Fig 4A). Mutation
291	probes for sites containing two mutations (i.e. N460K (AAA) and N460K (AAG), F486S and
292	F486V) use the same fluorescent dye for each mutation. The R346 and F486 probe sets use
293	unique, independent amplicons, whereas the K444 and N460 probe sets share a single,
294	common amplicon.
295	In order to determine the effectiveness of the dPCR probes to discriminate the identity of each
296	SNP, reactions containing the probe homologous to the mutation of interest and a probe
297	homologous to the reference sequence were assayed in a single reaction vessel. Each probe
298	pair was assayed using synthetically produced DNA templates containing the mutation
299	nucleotide sequence or reference nucleotide sequence. For each reaction, each probe
300	displayed a higher fluorescence signal to its homologous template, than to a template
301	containing a mismatching nucleotide (Fig 4B). Positive FAM fluorescence was observed from
302	assays with templates containing N460 or K444T residues. Positive VIC fluorescence was
303	observed from assays with templates containing N460K or K444 residues. Positive ABY
304	fluorescence was observed from assays with templates containing R346T or F486 residues.
305	Positive JUN fluorescence was observed from assays using templates containing R346, F486S, or

It is made available under a CC-BY-NC-ND 4.0 International license .

- 306 F486V templates. Together, this demonstrates that each probe can correctly discriminate
- templates differing by only a single SNP within the probe region.



Fig 4: Digital PCR assay for the detection of mutations associated with therapeutic monoclonal
 antibody evasion. (A) Schematic showing annealing locations of primers (black arrows) and
 probes (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities
 of dPCR microchambers for synthetic DNA constructs. Positive microchambers are those
 exceeding fluorescence thresholds (shaded regions).

It is made available under a CC-BY-NC-ND 4.0 International license .

315	The primers and probes from two assays were combined to assay the identity of two SNPs from
316	a single template. For each reaction, two amplicons were produced, with each amplicon
317	containing only a single substitution of interest. When assayed on synthetic DNA constructs,
318	each probe in the assays displayed higher fluorescence to its homologous template, than to a
319	mismatching template. The R346 and K444 assays were combined into single dPCR assay to
320	interrogate sequence identity at those positions simultaneously (Fig 5A). On the template
321	containing reference sequences, positive fluorescence was observed in VIC and JUN channels. A
322	positive response was observed in FAM and ABY channels for a template containing K444T and
323	R346T mutations, respectively.
324	The N460 and F486 assays were also combined into a single assay (Fig 5B). The reaction
325	contained a labeled probe for each reference sequence, a VIC-labeled probe for each N460K
326	codon (AAG and AAA), and a JUN-labeled probe for each F486 mutation (F486S and F486V). For
327	the reference sequence template, positive fluorescence responses were observed in the FAM
328	and ABY channels, and for both mutation templates positive responses were observed in the
329	VIC and JUN channels. An equivalent positive response was observed for the N460K AAG and
330	AAA codon probes as well as between the F486S and F486V probes, for their respective
331	templates.
332	The presence or absence of mutations at 4 SNP sites was able to be resolved in a single dPCR
333	reaction by using the mutation specific probes containing a different fluorescent dye for each

locus. Three amplicons were produced in each reaction, with the K444 and N460 probes sharing

- an amplicon. For each probe, fluorescence values were higher for its homologous template
- than to its mismatching template (Fig 5C). No positive response from any channel was observed

It is made available under a CC-BY-NC-ND 4.0 International license .

to a template containing the reference sequence at each position. Positive responses in the VIC,
ABY, and JUN channels were observed on a template containing N460K (AAG), R346T, and
F486V mutations. Positive responses in all four channels were observed on a template
containing the K444T, N460K (AAA), R346T, and F486S mutations. The number of positive
microchambers were similar between templates and probes, excepting the R346T probe having
a lower positive chamber count. These results demonstrate the versatility of dPCR assays to
report the identity of multiple nucleotide sequences across a template.



Fig 5: Representative microchamber fluorescence intensities for synthetic DNA constructs from
multiplexed dPCR assays. (A) R346 and K444 combination assay. (B) N460 and F486
combination assay. (C) Combination assay using R346T, K444T, N460K (AAA and AAG codons),
F486S, and F486V mutation probes. Positive microchambers are those exceeding fluorescence
thresholds (shaded regions).

It is made available under a CC-BY-NC-ND 4.0 International license .

351	In order to test the validity of these multiplexed RT-dPCR assays on clinical samples, we
352	performed dPCR and Illumina sequencing assays on human saliva samples. Saliva samples
353	containing SARS-CoV-2 infections from 8 lineages, previously identified by Illumina whole
354	genome sequencing, were used to evaluate the specificity of the assay to discriminate among
355	clinical specimens with varying mutation profiles. For each lineage, samples were examined
356	using an assay where the R346 and K444 assays were combined, an assay where the N460 and
357	F486 assays were combined, and an assay where all 6 mutation-specific probes were used.
358	The combined R346 and K444 assay was able to correctly discriminate between the mutation
359	and reference sequence at each locus (Fig 6A). FAM fluorescence was observed in the BQ.1 and
360	BQ.1.1 lineages, which contain the K444T mutation. Positive VIC fluorescence was seen in
361	samples from the BA.2, BA.2.75.2, BM.1.1, BN.1, BA.5, and BF.7 lineages, consistent with the
362	presence of the reference sequence at the K444 locus. While the XBB lineage contains the
363	reference amino acid at K444 and V445P mutation. The V445P mutation is not present in the
364	reference-specific probe and causes failure at this position. A positive ABY response was seen in
365	the BA.2.75.2, BM.1.1, BN.1, BF.7, BQ.1.1, and XBB lineages, which contain the R346 mutation.
366	Finally, JUN fluorescence properly identified the presence of the reference sequence at R346 in
367	the BA.2, BA.5, and BQ.1 lineages. A reduced positivity response of the R346 probes was also
368	observed on the saliva samples, as seen with the synthetic DNA constructs. Thirty-two total
369	samples were tested on the combined assay and gave results consistent with their Illumina
370	whole genome sequencing determination (see Supplementary Dataset 3 in the supplemental
371	material).

It is made available under a CC-BY-NC-ND 4.0 International license .

372	Sequence composition of saliva samples was correctly identified using the N460 and F486
373	combined assays (Fig 6B). Positive FAM fluorescence was observed in the BA.2, BA.5, and BF.7
374	lineages, which contain the reference nucleotide sequence at N460. Positive VIC fluorescence
375	was observed in the BA.2.75.2, BM.1.1, BN.1, BQ.1, BQ.1.1, and XBB lineages, consistent with
376	the presence of the N460K mutation in these lineages. Positive ABY fluorescence was observed
377	in the BA.2 and BA.5 lineages, which have the reference nucleotide sequence at F486. Positive
378	JUN fluorescence was observed in BA.2.75.2, BM.1.1, BA.5, BF.7, BQ.1, BQ.1.1, and XBB
379	lineages, which contain either the F486S or F486V mutations. Twenty-eight total samples were
380	tested on the combined assay and gave results consistent with their Illumina whole genome
381	sequencing determination (see Supplementary Dataset 4 in the supplemental material).
382	An assay comprised of the 6 mutation-specific probes was also verified on saliva samples and
383	gave appropriate responses to mutation composition (Fig 6C). Positive FAM fluorescence was
384	observed in the BQ.1 and BQ.1.1 lineages, consistent with the presence of the K444T mutation.
385	Positive VIC fluorescence was observed in the BA.2.75.2, BM.1.1, BN.1, BQ.1, BQ.1.1, and XBB
386	lineages, consistent with the presence of either N460K mutation (AAG or AAA codon). Positive
387	ABY fluorescence was observed in the BA.2.75.2, BM.1.1, BN.1, BF.7, BQ.1.1, and XBB lineages,
388	consistent with the presence of the R346T mutation. Positive JUN fluorescence was observed in
389	the BA.2.75.2, BM.1.1, BA.5, BF.7, BQ.1, BQ.1.1, and XBB lineages, consistent with the presence
390	of either the F486S or F486V mutations. No positive fluorescence response was observed in the
391	BA.2 lineage, which contains none of the screened mutations. As in the R346/K444 combination
392	assay, the XBB lineage failed to display FAM fluorescence due to the absence of the K444T
393	mutation and the presence of the V445P mutation. We tested this assay on 75 total saliva

It is made available under a CC-BY-NC-ND 4.0 International license .

- 394 samples, and all samples displayed results consistent with their respective Illumina whole
- 395 genome sequencing lineage designation (see Supplementary Dataset 5 in the supplemental
- 396 material). These assays illustrate that dPCR can discern immunologically relevant SARS-CoV-2
- 397 mutations from saliva specimens and could be used to guide therapeutic treatment.

It is made available under a CC-BY-NC-ND 4.0 International license .



It is made available under a CC-BY-NC-ND 4.0 International license .

Fig 6: Representative microchamber fluorescence intensities for clinical saliva specimens from
multiplexed dPCR assays. (A) R346 and K444 combination assay. (B) N460 and F486
combination assay. (C) Combination assay using R346T, K444T, N460K (AAA and AAG codons),
F486S, and F486V mutation probes. Positive microchambers are those exceeding fluorescence
thresholds (shaded regions).

404

405 **DISCUSSION**

In this study we demonstrated the robustness of using digital PCR in genotyping SARS-CoV-2 406 positive saliva samples for two use cases: lineage classification and therapeutic mAb resistance. 407 408 We showed that using a mixture of probes with a common fluorescent dye can be used to 409 identify mutants when multiple nucleotide substitutions are at one region of interest (N460 and F486 assays, Fig 4B). This is particularly useful when an amino acid is encoded by multiple 410 411 codons, or multiple amino acids are of interest. We also demonstrated that detection is not compromised when multiple probes bind to different locations on a single amplicon 412 413 (N460/F486 assay, **Fig 5C**). This property is beneficial when interrogating multiple mutations within a single domain of a protein (e.g. the RBD of the s gene) where creating multiple 414 amplicons could be difficult due to primer constraints. Finally, we demonstrated that these 415 assays can be performed on nucleic acids extracted from saliva samples to detect the presence 416 of specific SARS-CoV-2 mutations. 417

The R346, K444, N460, and F486 residues are locations of key mutations important in
neutralization escape, enhanced fusogenicity, and enhanced S protein processing. Structural

It is made available under a CC-BY-NC-ND 4.0 International license .

420	modeling suggests that R346T and K444T appear to disrupt salt bridge formation between S
421	protein and class III monoclonal antibodies (e.g. cilgavimab), lowering effectiveness (12, 29).
422	The N460K mutation has been shown to enhance S protein processing and is predicted to
423	facilitate a salt bridge and hydrogen bond formation between Spike and human ACE2,
424	enhancing cell fusion (30). The F486V mutation aided in evading serum neutralization by early
425	BA.5 lineages, but more recent lineages containing the F486S mutation are even more resistant
426	to neutralization (31). Beyond the mutations examined here, additional mutations at these loci
427	have been implicated in immune escape and are rising in frequency (11).
428	There are limitations to the use of dPCR for SNP identification. Since dPCR relies on sequence
429	homology between probes, primers, and template nucleic acids, it is susceptible to failure as
430	SARS-CoV-2 evolves mutations. There have been numerous reports of SARS-CoV-2 mutations
431	that cause failure on diagnostic RT-PCR assays (32-34). Mutations in other nucleotides of the
432	probe or primer binding regions will result in failed amplification, as observed with the K444
433	reference probe against the XBB lineage (Fig 6A), and could result in sequence misclassification.
434	Furthermore, caution must be exercised interpreting negative results of reactions containing
435	only a single probe for each SNP of interest (i.e. 6 mutant probe, 4 SNP assay; Fig 6C). Results
436	from lineages containing no mutations of interest, such as BA.2, are indistinguishable from
437	failed assays and samples with concentrations below the limit of detection. This limitation could
438	be overcome using a universally binding probe that would always provide a fluorescent
439	response but doing so would reduce the total number of SNP sites being interrogated in a single
440	reaction.

It is made available under a CC-BY-NC-ND 4.0 International license .

441	As new variants emerge, the effectiveness of current antibody therapies is at risk. At their
442	emergence, the initial Omicron variants were less sensitive to antibody treatments
443	bamlanivimab and etesevimab (joint administration) and REGEN-COV (casirivimab and
444	imdevimab), and their use was curtailed (35). More recent variants have caused the recall of
445	emergency use authorization for bebtelovimab, leaving Paxlovid (nirmatrelivir/ritonavir) and
446	remdesivir as preferred treatment options (36). These treatments are also at risk, as in vitro
447	analysis using a Vesicular Stomatitis Virus system has identified that Y54C, G138S, L167F,
448	Q192R, A194S and F305L mutations in nsp5 (3-cymotrypsin like protease) could result in
449	reduced Paxlovid efficacy (37). As demonstrated in this study, a similar dPCR approach could be
450	used to determine resistance to Paxlovid. Due to the very rapid development of resistance
451	mutations in SARS-CoV-2 (38) there is an increased need for versatile assays to guide patient
452	treatment and extend the use of life-saving therapeutics. The use of digital PCR to clarify active
453	infection (39), determine SARS-CoV-2 lineages, and pinpoint therapeutically relevant mutations
454	make it a well-suited technology for use in personalized diagnostics.
455	

456

457 ACKNOWLEDGEMENTS

458 We thank the authors from originating laboratories responsible for obtaining the specimens 459 and the submitting laboratories where genetic sequence data were generated and shared via 460 the GISAID initiative, on which part of the research is based.

461

It is made available under a CC-BY-NC-ND 4.0 International license .

462 FUNDING

- 463 This research was funded by the Arizona Department of Health Services (CTR053916), the
- 464 Centers for Disease Control and Prevention (CDC BAA 75D30121C11084) and Tohono O'Odham
- 465 Nation (2020-01 ASU).

466

467 **ABBREVIATIONS**

- 468 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- 469 Coronavirus Disease 2019 (COVID-19)
- 470 Reverse transcription-digital polymerase chain reaction (RT-dPCR)
- 471 Variant of concern (VOC)

472

473 AVAILABILITY OF DATA AND MATERIALS

- 474 Genome sequences have been deposited to the GISAID repository. Scripts for data curation can
- 475 be found on the Lim lab GitHub (<u>https://github.com/ASU-Lim-Lab/Absolute-Q</u>).

476

477 **COMPETING INTERESTS**

478 The authors declare no competing interests.

It is made available under a CC-BY-NC-ND 4.0 International license .

480 AUTHOR CONTRIBUTIONS

- 481 Conceptualization: S.C.H. and E.S.L.; data curation: S.C.H., L.A.H., M.B.L., J.C.H, M.F.S; formal
- 482 analysis: S.C.H., L.A.H., M.F.S.; funding acquisition: E.S.L.; investigation: S.C.H., L.A.H., M.L.,
- 483 M.F.S., J.C.H.; supervision: E.S.L.; writing original draft: S.C.H. and E.S.L.; writing review and
- editing S.C.H. and E.S.L. All authors have read and agreed to the published version of the
- 485 manuscript.

486 **REFERENCES**

- Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. 2021.
 The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 22:757 773.
- Centers for Disease Control and Prevention. 2022. COVID Data Tracker, *on* US Department of
 Health and Human Services, CDC. <u>https://covid.cdc.gov/covid-data-tracker</u>. Accessed 2022-12 13.
- 493 3. World Health Organization. 2021. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief
 494 and Priority Actions for Member States. <u>https://www.who.int/docs/default-</u>
 495 source/coronaviruse/technical-brief-and-priority-action-on-omicron.pdf?sfvrsn=50732953 3.
- 495 <u>Source/coronaviruse/technical-brief-and-priority-action-on-omicron.pdf/sivrsh=50/32953_3</u>. 496 Accessed 2022/11/14.
- 497 4. Du P, Gao GF, Wang Q. 2022. The mysterious origins of the Omicron variant of SARS-CoV-2.
 498 Innovation (Camb) 3:100206.
- 499 5. Sun Y, Lin W, Dong W, Xu J. 2022. Origin and evolutionary analysis of the SARS-CoV-2 Omicron
 500 variant. J Biosaf Biosecur 4:33-37.
- Smith MF, Holland SC, Lee MB, Hu JC, Pham NC, Sullins RA, Holland LA, Mu T, Thomas AW, Fitch
 R, Driver EM, Halden RU, Villegas-Gold M, Sanders S, Krauss JL, Nordstrom L, Mulrow M, White
 M, Murugan V, Lim ES. in press. Baseline sequencing surveillance of public clinical testing,
 hospitals, and community wastewater reveals rapid emergence of SARS-CoV-2 Omicron variant
 of concern in Arizona, USA. mBio.
- 506 7. Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y, Zhang Y, Pan T, Zhang H, He X. 2021. SARS-CoV-2
 507 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal
 508 Transduct Target Ther 6:430.
- McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, Hauser K, Joshi A,
 Stewart C, Dillen JR, Powell AE, Croll TI, Nix J, Virgin HW, Corti D, Snell G, Veesler D. 2021.
 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science
 375:864-868.
- 5139.Chen J, Wang R, Gilby NB, Wei GW. 2022. Omicron Variant (B.1.1.529): Infectivity, Vaccine514Breakthrough, and Antibody Resistance. J Chem Inf Model 62:412-422.
- 51510.Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, Wang J, An R, Chen X, Zhang N, Wang Y, Wang P,516Zhao L, Sun H, Yu L, Yang S, Niu X, Xiao T, Gu Q, Shao F, Hao X, Xu Y, Jin R, Shen Z, Wang Y, Xie

517		XS. 2022. Imprinted SARS-CoV-2 humoral immunity induces converging Omicron RBD evolution.
518		bioRxiv doi:10.1101/2022.09.15.507787.
519	11.	Focosi D, McConnell S, Casadevall A. 2022. The Omicron variant of concern: Diversification and
520		convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies. Drug
521		Resist Updat 65:100882.
522	12.	Qu P, Evans JP, Faraone JN, Zheng YM, Carlin C, Anghelina M, Stevens P, Fernandez S, Jones D,
523		Lozanski G, Panchal A, Saif LJ, Oltz EM, Xu K, Gumina RJ, Liu SL. 2022. Enhanced neutralization
524		resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell
525		Host Microbe doi:10.1016/j.chom.2022.11.012.
526	13.	US FDA. 2022. FDA announces bebtelovimab is not currently authorized in any US region.
527		https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-
528		currently-authorized-any-us-region. Accessed 2022-12-11.
529	14.	Butchbach ME. 2016. Applicability of digital PCR to the investigation of pediatric-onset genetic
530		disorders. Biomol Detect Quantif 10:9-14.
531	15.	Navarro E, Serrano-Heras G, Castano MJ, Solera J. 2015. Real-time PCR detection chemistry. Clin
532		Chim Acta 439:231-50.
533	16.	Kutyavin IV, Afonina IA, Mills A, Gorn VV, Lukhtanov EA, Belousov ES, Singer MJ, Walburger DK,
534		Lokhov SG, Gall AA, Dempcy R, Reed MW, Meyer RB, Hedgpeth J. 2000. 3'-minor groove binder-
535		DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res
536		28:655-61.
537	17.	Jiang L, Lin R, Gallagher S, Zayac A, Butchbach MER, Hung P. 2020. Development and validation
538		of a 4-color multiplexing spinal muscular atrophy (SMA) genotyping assay on a novel integrated
539		digital PCR instrument. Sci Rep 10:19892.
540	18.	Sedlak RH, Cook L, Cheng A, Magaret A, Jerome KR. 2014. Clinical utility of droplet digital PCR for
541		human cytomegalovirus. J Clin Microbiol 52:2844-8.
542	19.	Lo YM, Lun FM, Chan KC, Tsui NB, Chong KC, Lau TK, Leung TY, Zee BC, Cantor CR, Chiu RW.
543		2007. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad
544		Sci U S A 104:13116-21.
545	20.	Caduff L, Dreifuss D, Schindler T, Devaux AJ, Ganesanandamoorthy P, Kull A, Stachler E,
546		Fernandez-Cassi X, Beerenwinkel N, Kohn T, Ort C, Julian TR. 2022. Inferring transmission fitness
547		advantage of SARS-CoV-2 variants of concern from wastewater samples using digital PCR,
548		Switzerland, December 2020 through March 2021. Euro Surveill 27.
549	21.	ARTIC Network. 2022. artic-network/primer-schemes/nCOV-2019. https://github.com/artic-
550		network/primer-schemes/tree/master/nCoV-2019/V4. Accessed 2022-12-01.
551	22.	Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.
552		arXiv 1303.3997.
553	23.	Castellano S, Cestari F, Faglioni G, Tenedini E, Marino M, Artuso L, Manfredini R, Luppi M, Trenti
554		T, Tagliafico E. 2021. iVar, an Interpretation-Oriented Tool to Manage the Update and Revision
555		of Variant Annotation and Classification. Genes (Basel) 12.
556	24.	Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG. 2020. A
557		dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat
558		Microbiol 5:1403-1407.
559	25.	Schaffer AA, Hatcher EL, Yankie L, Shonkwiler L, Brister JR, Karsch-Mizrachi I, Nawrocki EP. 2020.
560		VADR: validation and annotation of virus sequence submissions to GenBank. BMC Bioinformatics
561		21:211.
562	26.	Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher
563		RA. 2018. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34:4121-4123.

It is made available under a CC-BY-NC-ND 4.0 International license .

564 565	27.	Chen C, Nadeau S, Yared M, Voinov P, Xie N, Roemer C, Stadler T. 2021. CoV-Spectrum: Analysis of Globally Shared SARS-CoV-2 Data to Identify and Characterize New Variants. Bioinformatics			
566		38:1735-7.			
567	28.	Jessen R, Nielsen L, Larsen NB, Cohen AS, Gunalan V, Marving E, Alfaro-Nunez A, Polacek C,			
568		Danish C-GC, Fomsgaard A, Spiess K. 2022. A RT-qPCR system using a degenerate probe for			
569		specific identification and differentiation of SARS-CoV-2 Omicron (B.1.1.529) variants of			
570		concern. PLoS One 17:e0274889.			
571	29.	Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, Liu M, Wang M, Yu J, Shah JG, Chang JY, Herbas F,			
572		Yin MT, Sobieszczyk ME, Sheng Z, Liu L, Ho DD. 2022. Resistance of SARS-CoV-2 omicron			
573		subvariant BA.4.6 to antibody neutralisation. Lancet Infect Dis 22:1666-1668.			
574	30.	Qu P, Evans JP, Zheng YM, Carlin C, Saif LJ, Oltz EM, Xu K, Gumina RJ, Liu SL. 2022. Evasion of			
575		neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. Cell Host Microbe 30:1518-			
576		1526 e4.			
577	31.	Sheward DJ, Kim C, Fischbach J, Sato K, Muschiol S, Ehling RA, Bjorkstrom NK, Karlsson			
578		Hedestam GB, Reddy ST, Albert J, Peacock TP, Murrell B. 2022. Omicron sublineage BA.2.75.2			
579		exhibits extensive escape from neutralising antibodies. Lancet Infect Dis 22:1538-1540.			
580	32.	Amato L, Jurisic L, Puglia I, Di Lollo V, Curini V, Torzi G, Di Girolamo A, Mangone I, Mancinelli A,			
581		Decaro N, Calistri P, Di Giallonardo F, Lorusso A, D'Alterio N. 2021. Multiple detection and			
582		spread of novel strains of the SARS-CoV-2 B.1.177 (B.1.177.75) lineage that test negative by a			
583		commercially available nucleocapsid gene real-time RT-PCR. Emerg Microbes Infect 10:1148-			
584		1155.			
585	33.	Holland SC, Bains A, Holland LA, Smith MF, Sullins RA, Mellor NJ, Thomas AW, Johnson N,			
586		Murugan V, Lim ES. 2022. SARS-CoV-2 Delta Variant N Gene Mutations Reduce Sensitivity to the			
587		TaqPath COVID-19 Multiplex Molecular Diagnostic Assay. Viruses 14.			
588	34.	Vanaerschot M, Mann SA, Webber JT, Kamm J, Bell SM, Bell J, Hong SN, Nguyen MP, Chan LY,			
589		Bhatt KD, Tan M, Detweiler AM, Espinosa A, Wu W, Batson J, Dynerman D, Wadford DA,			
590		Puschnik AS, Neff N, Ahyong V, Miller S, Ayscue P, Tato CM, Paul S, Kistler AL, DeRisi JL, Crawford			
591		ED. 2020. Identification of a Polymorphism in the N Gene of SARS-CoV-2 That Adversely Impacts			
592		Detection by Reverse Transcription-PCR. J Clin Microbiol 59.			
593	35.	National Institutes of Health. 2022. Anti-SARS-CoV-2 Monoclonal Antibodies.			
594		https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibodv-			
595		products/anti-sars-cov-2-monoclonal-antibodies/. Accessed			
596	36.	US FDA. 2022. Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal			
597		Antibodies to Treat COVID-19 Due to the Omicron Variant. https://www.fda.gov/news-			
598		events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-			
599		antibodies-treat-covid-19-due-omicron. Accessed 2022-12-10.			
600	37.	Heilmann E, Costacurta F, Volland A, von Laer D. 2022. SARS-CoV-2 3CLpro mutations confer			
601		resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system.			
602		BioRxiv doi:10.1101/2022.07.02.495455.			
603	38.	Rockett R, Basile K, Maddocks S, Fong W, Agius JE, Johnson-Mackinnon J, Arnott A, Chandra S,			
604		Gall M, Draper J, Martinez E, Sim EM, Lee C, Ngo C, Ramsperger M, Ginn AN, Wang Q, Fennell M,			
605		Ko D, Lim HL, Gilroy N, O'Sullivan MVN, Chen SC, Kok J, Dwyer DE, Sintchenko V. 2022.			
606		Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use. N Engl J Med 386:1477-			
607		1479.			
608	39.	Hwang HS, Lo CM, Murphy M, Grudda T, Gallagher N, Luo CH, Robinson ML, Mirza A, Conte M,			
609		Conte A, Zhou R, Vergara C, Brooke CB, Pekosz A, Mostafa HH, Manabe YC, Thio CL, Balagopal A.			
610		2022. Characterizing SARS-CoV-2 transcription of subgenomic and genomic RNAs during early			
611		human infection using multiplexed droplet digital PCR. J Infect Dis doi:10.1093/infdis/jiac472.			

It is made available under a CC-BY-NC-ND 4.0 International license .

6	1	2
υ	т	2

- 613
- 614

615 FIGURE LEGENDS

616 Fig 1: Digital PCR assay for the determination of the Delta, Omicron BA.1, and Omicron BA.2 617 lineages. (A) Schematic showing annealing locations of primers (black arrows) and probes 618 (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities of dPCR microchambers for synthetic DNA constructs. Positive microchambers are those exceeding 619 fluorescence thresholds (shaded regions). (C) Number of positive microchambers (maximum 620 621 number of chambers is 20480) resulting from each saliva sample. Samples are grouped by 622 Illumina sequencing lineage determination and sorted by positive microchamber count of the 623 respective lineage-specific probe. Dotted line indicates the positive threshold value (9 624 microchambers). Fig 2: Digital PCR assay for the determination of the Omicron BA.1, and Delta or Omicron BA.2 625 626 lineages. (A) Schematic showing annealing locations of primers (black arrows) and probes (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities of dPCR 627 628 microchambers for synthetic DNA constructs. Positive microchambers are those exceeding 629 fluorescence thresholds (shaded regions). (C) Number of positive microchambers (maximum number of chambers is 20480) resulting from each saliva sample. Samples are grouped by 630 Illumina sequencing lineage determination and sorted by positive microchamber count of the 631

It is made available under a CC-BY-NC-ND 4.0 International license .

- 632 respective lineage-specific probe. Dotted line indicates the positive threshold value (9
- 633 microchambers).
- **Fig 3:** Phylogenetic distribution of mutations that evade therapeutic monoclonal antibodies. (A)
- 635 Phylogenetic tree of representative circulating sublineages. Colored circles indicate the
- 636 presence of a Spike RBD mutation found in at least 75% of sequences within that lineage.
- Global frequency, phylogenetic distribution, and codon frequencies for R346T (B), K444T (C),
- 638 N460K (D), F486S (E), and F486V (F) mutations.
- **Fig 4:** Digital PCR assay for the detection of mutations associated with therapeutic monoclonal
- 640 antibody evasion. (A) Schematic showing annealing locations of primers (black arrows) and
- 641 probes (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities
- of dPCR microchambers for synthetic DNA constructs. Positive microchambers are those
- 643 exceeding fluorescence thresholds (shaded regions).
- **Fig 5:** Representative microchamber fluorescence intensities for synthetic DNA constructs from
- 645 multiplexed dPCR assays. (A) R346 and K444 combination assay. (B) N460 and F486
- 646 combination assay. (C) Combination assay using R346T, K444T, N460K (AAA and AAG codons),
- 647 F486S, and F486V mutation probes. Positive microchambers are those exceeding fluorescence
- 648 thresholds (shaded regions).
- 649 **Fig 6:** Representative microchamber fluorescence intensities for clinical saliva specimens from
- 650 multiplexed dPCR assays. (A) R346 and K444 combination assay. (B) N460 and F486
- 651 combination assay. (C) Combination assay using R346T, K444T, N460K (AAA and AAG codons),

It is made available under a CC-BY-NC-ND 4.0 International license .

- 652 F486S, and F486V mutation probes. Positive microchambers are those exceeding fluorescence
- 653 thresholds (shaded regions).
- **Fig S1**: Failure frequency of probes (A) and primers (B) used in the *spike* RBD digital PCR assays.
- 655 **Table S1**: Digital PCR probe sequences and modifications
- 656 **Table S2**: Digital PCR primer sequences
- 657 **Table S3**: Digital PCR synthetic DNA templates used in
- 658 Supplementary Dataset 1: Number of positive wells passing threshold value and metadata for
- each specimen in the Orf1ab_3395 assay
- 660 Supplementary Dataset 2: Number of positive wells passing threshold value and metadata for
- 661 each specimen in the spike 143 deletion assay
- 662 **Supplementary Dataset 3**: Number of positive wells passing threshold value and metadata for
- each specimen in the R346/K444 combined assay
- 664 **Supplementary Dataset 4**: Number of positive wells passing threshold value and metadata for
- each specimen in the N460/F486 combined assay
- 666 Supplementary Dataset 5: Number of positive wells passing threshold value and metadata for
- 667 each specimen in the 6 mutation probe assay